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Abstract
Mitochondria are deeply involved in the production of reactive oxygen species through one-electron carriers in the
respiratory chain; mitochondrial structures are also very susceptible to oxidative stress as evidenced by massive information
on lipid peroxidation, protein oxidation, and mitochondrial DNA (mtDNA) mutations. Oxidative stress can induce
apoptotic death, and mitochondria have a central role in this and other types of apoptosis, since cytochrome c release in the
cytoplasm and opening of the permeability transition pore are important events in the apoptotic cascade. The discovery that
mtDNA mutations are at the basis of a number of human pathologies has profound implications: maternal inheritance of
mtDNA is the basis of hereditary mitochondrial cytopathies ; accumulation of somatic mutations of mtDNA with age has
represented the basis of the mitochondrial theory of ageing, by which a vicious circle is established of mtDNA damage,
altered oxidative phosphorylation and overproduction of reactive oxygen species. Experimental evidence of respiratory chain
defects and of accumulation of multiple mtDNA deletions with ageing is in accordance with the mitochondrial theory,
although some other experimental findings are not directly ascribable to its postulates. ß 1998 Elsevier Science B.V. All
rights reserved.
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1. Introduction
After the elucidation of the major aspects of en-
ergy conservation in oxidative phosphorylation, the
declined interest in mitochondria received a novel
impetus by discoveries of cell biology and pathology.
Two major developments opened breakthroughs in
mitochondrial pathology: ¢rst, the discovery that mi-
tochondrial DNA (mtDNA) mutations are at the
basis of diseases [1], and second, the unexpected
role of mitochondria in the mechanisms of cell death
[2]. A common denominator of these aspects is the
role of reactive oxygen species (ROS). This article
attempts to provide a rationale for the role of oxida-
tive stress by ROS on di¡erent aspects of pathology
where mitochondria seem to have a major role.
There is almost no area of human pathology where
oxidative stress has not been implicated [3,4]; this
review, therefore, will be restricted to few selected
topics and will be centered on the role of mitochon-
dria in ageing.
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2. Mitochondria as sources of ROS
Reactive oxygen species [5,6] include oxygen free
radicals (the superoxide radical anion, as the primary
product of one-electron dioxygen reduction [7,8], and
the extremely aggressive hydroxyl radical deriving
from subsequent chemical reactions [9]), singlet oxy-
gen and strong non-radical oxidants such as hydro-
gen peroxide; furthermore nitric oxide and the de-
rived peroxynitrite radical [10] can be included in this
category.
Sources of ROS in living cells are represented by
physiological enzymatic mechanisms [11]; oxidative
stress [11] may ensue when ROS production is exces-
sive, due either to a particular metabolic situation, or
to the presence of xenobiotic compounds [12], or also
to damage-mediated liberation of non-enzymatic cat-
alysts such as free metals [13,14], or when the cellular
defences are lowered by the depletion of physiolog-
ical antioxidants.
Among the cellular sources of ROS, besides spe-
ci¢c enzyme systems involved in phagocytosis [8],
eicosanoid metabolism [15] and nitric oxide produc-
tion [16], are cytoplasmic systems such as xanthine
oxidase [4], that can be formed from xanthine dehy-
drogenase by oxidation of thiol groups [17], micro-
somal P450 oxygenases and quinone reductases [18],
and the mitochondrial respiratory chain [19].
The respiratory chain is a powerful source of ROS,
primarily the superoxide radical and consequently
hydrogen peroxide, either as a product of superoxide
dismutase [7] or by spontaneous disproportionation.
It is calculated that 1^4% of oxygen reacting with the
respiratory chain is incompletely reduced to ROS
[20,21]. Their production may increase in state 4
with respect to state 3 [22], because O2 concentration
increases and the level of reduced one-electron do-
nors in the respiratory chain is concomitantly in-
creased [23]. A similar result is obtained when cyto-
chrome oxidase activity is lowered, since this leads to
the concomitant raise of oxygen concentration and
of the reduced state of one-electron donors in the
respiratory chain [24]. According to Skulachev [25],
uncoupled electron transfer chains, by enhancing
oxygen consumption, represent a device for prevent-
ing or decreasing ROS production by mitochondria.
There are two major respiratory chain regions
where ROS are produced, one being complex I
(NADH coenzyme Q reductase) [8,20,26^28] and
the other complex III (ubiquinol cytochrome c reduc-
tase) [8,28^30].
In complex III, antimycin is known not to com-
pletely inhibit electron £ow from ubiquinol to cyto-
chrome c : the antimycin-insensitive reduction of cy-
tochrome c is mediated by superoxide radicals; the
source of superoxide in the enzyme may be either
cytochrome b566, [31] or ubisemiquinone [32] or Ries-
ke’s iron-sulfur center [33]. Ubisemiquinone is rela-
tively stable only when protein bound [34], therefore
the coenzyme Q (CoQ) pool in the lipid bilayer is no
source of ROS.
The role of ubiquinone within ROS production
deserves some comments (cf. [18]), since it has been
described both as a prooxidant [22,28,32] and as a
powerful antioxidant [35^37]; the former action has
been ascribed to either oxidized or reduced quinone,
whereas the latter exclusively to ubiquinol.
In some instances, a prooxidant e¡ect may be as-
cribed only apparently to CoQ: for example the en-
hanced ROS production when CoQ-depleted mito-
chondria oxidizing succinate are reconstituted with
CoQ [22] is a consequence of the increased rate of
electron feeding to complex III via the quinone, and
presumably complex III itself is the source of ROS
generation.
Early experiments proved the involvement of com-
plex I in ROS production [38]; addition of either
NADH at low concentration or of NADPH, which
feeds the electrons at decreased rate into the com-
plex, led to copious ROS production detected by
lipid peroxidation; on the other hand, addition
of NADH at high concentration, but in the presence
of rotenone, also induced peroxidation. In another
study [28] water-soluble CoQ homologs used as
electron acceptors from isolated complex I stim-
ulated H2O2 production in the order
CoQ1sCoQ0sCoQ2, whereas CoQ6 and CoQ10
were inactive; the rate of H2O2 production was
partly inhibited by rotenone, indicating that water-
soluble quinones may react with oxygen when re-
duced at sites both prior and subsequent to the ro-
tenone block. There is evidence that the one-electron
donor to oxygen in complex I is a non-physiological
quinone reduction site di¡erent from the physiolog-
ical site(s) [39^41]; the former, hydrophilic, site re-
duces several quinones to the corresponding semiqui-
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none forms, which are unstable and can reduce oxy-
gen to superoxide. This mechanism is shared by sev-
eral quinones, including such drugs as anthracyclines
[42] and the clinically employed CoQ analog, idebe-
none [43]. However, auto-oxidation of fully reduced
quinones [18], such as those formed by NADH CoQ
reductase past the rotenone inhibition site, is also a
source of ROS, but this e¡ect exclusively pertains to
hydrophilic quinones, and not to the physiological
hydrophobic ubiquinol. Finally, in view of the ex-
periments of Takeshige et al. [38], the hydrophilic,
rotenone-insensitive, site can apparently reduce oxy-
gen to superoxide in the absence of intermediate ac-
ceptors.
To conclude about the role of CoQ, it is clear that
hydrophobic ubiquinones, such as the physiological
CoQ10 for man, do not behave as prooxidants in
mitochondria; on the contrary, all evidence points
out that they behave as antioxidants in their reduced
form [35^37]; possibly, their deep membrane inser-
tion prevents contact with non-physiological reduc-
tion sites, and they are not auto-oxidizable. The
mechanism by which reduced CoQ functions as an
antioxidant in vivo is out of the scope of this review
and is discussed at length elsewhere [35^37].
ROS production by the respiratory chain is in-
creased after a period of anoxia, when the oxygen
concentration is reestablished by reperfusion [44^
46]; one reason, besides those pointed out above
(sudden high oxygen concentration in the presence
of the respiratory chain in the reduced state), may
be that the anoxic period, by depleting ATP, has
induced damage to cellular structures and released
catalytic metals [47], such as iron and copper, which
are abundant in the inner mitochondrial membrane.
Mitochondria contain antioxidant enzymes, in-
cluding superoxide dismutase (Mn form) [48,49]
and glutathione peroxidase [50], and lipid-soluble
antioxidants such as vitamin E [51] and reduced
CoQ [52]. Ubiquinol may exert its antioxidant func-
tion indirectly by reducing K-tocopheroxyl radical
back to vitamin E [53] or directly as a quencher of
oxygen and lipid peroxyl radicals [54,55].
3. Mitochondria as targets of ROS
Being major producers of ROS, mitochondrial
structures are exposed to high concentrations thereof
and may therefore be particularly susceptible to their
attack. Evidence exists, however, that even ROS pro-
duced outside the mitochondrion may damage mito-
Fig. 1. A scheme of oxidative stress-induced apoptosis (cf. [113,159]). See text for explanations. MPT, mitochondrial permeability tran-
sition; AIF, apoptosis inducing factor. Mitochondrial activation refers to an early unknown step (steps) within the bulk of phenomena
occurring at the mitochondrial level in the apoptotic cascade.
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chondrial components: decreases of respiratory en-
zyme activities and of mitochondrial membrane po-
tential, induced by adriamycin in perfused rat liver
[56] or isolated hepatocytes [57], are prevented by
incubation with CoQ10 ; the exogenous quinone is
taken up by the intracellular compartment but is
not incorporated in the mitochondria under the con-
ditions of the experiments [58], suggesting that the
radicals quenched by CoQ are also produced in the
extramitochondrial compartment.
Damage by oxidative stress to mitochondrial com-
ponents includes lipid peroxidation, protein oxida-
tion and mtDNA mutations.
Lipid peroxidation [14,59^61] might be particu-
larly harmful in mitochondria, that contain cardio-
lipin as a major component of the inner mitochon-
drial membrane [62], since this lipid is required for
the activity of cytochrome oxidase [63] and of other
mitochondrial proteins [64]. Oxidative stress de-
creases cardiolipin to a larger extent than other lipids
[65,66], perhaps as a consequence of its high unsatu-
ration [67]; cardiolipin decrease appears to be di-
rectly related to reversible decrease of cytochrome
oxidase activity [68,69].
Protein oxidation as a result of oxidative stress
may occur either directly or as a consequence of lipid
peroxidation [70^73]; it has been described to a¡ect
respiratory chain enzymes [74], ATPase [73^76], the
adenine nucleotide translocator [77] and transhydro-
genase [78] and to determine opening of the perme-
ability transition pore [79]. To this respect, it is worth
emphasizing the striking susceptibility of the adenine
nucleotide translocator to oxidative stress [77], since
this protein is considered part of the permeability
transition pore [80] (cf. [81] for review). Complex I
is particularly susceptible to oxidative damage [82],
and its decreased activity in Parkinson’s disease may
be linked to an enhanced production of ROS and to
the consequent damage of the complex [83]. Modi¢-
cation of the redox state of vital sulfhydryl groups
may be at the basis also in mitochondria of impor-
tant regulatory mechanisms, similar to those sug-
gested to modulate signal transduction cascades
[84]. Inactivation of Mn-superoxide dismutase in
transgenic mice [85] enhances ROS production and
results in animal death by dilated cardiomyopathy,
with partial inactivation of mitochondrial enzymes
containing iron-sulfur centers.
Fig. 2. A vicious circle of oxidative stress and mtDNA mutations in cell death and ageing (freely redrawn from [159,218]).
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Of special interest is damage to mtDNA [86^89],
since this small molecule is extremely susceptible to
oxidative damage: being located in the matrix, it is
close to the major source of ROS; moreover, lacking
introns and being devoid of histones and other
DNA-associated proteins, the probability of oxida-
tive modi¢cation of a coding region of mtDNA is
very high. After an oxidative stress to cultured cells,
the damage to mtDNA is higher and persists longer
than that to nuclear DNA [90], indicating that the
repair devices of the former, even if present, are
largely insu⁄cient to overcome extensive DNA dam-
age [91].
ROS were shown to induce extensive fragmenta-
tion and deletions in mtDNA; up to 187 di¡erent
deletions were listed by Ozawa after the third day
of an oxidative stress to a transformed human ¢bro-
blast cell line [92]. The 8-hydroxy-D-guanosine con-
tent is considered a marker of oxidative damage to
DNA [93]; its increased content in mtDNA has been
reported in ageing [93^95] and age-associated dis-
eases [96^98].
4. Mitochondria, ROS, and cell death
Cell death can occur by either necrosis or apopto-
sis [99] as a result of exogenous and endogenous
insults. There seems to be no net border between
these phenomena [100], depending mainly on the ex-
tent of stress [101] and on the ATP levels [102]; how-
ever, the mechanisms are rather di¡erent, since apop-
tosis involves a well de¢ned chain of enzymatic
events which are genetically programmed [103].
Apoptosis induced by oxidative stress has been well
documented [92,101,104^106] and appears to involve
the same steps in the commitment and execution
stages as in the other causes of apoptosis [105,106].
Actually, apoptosis may be a mechanism to eliminate
ROS-producing cells [107].
A recent exciting development has been the discov-
ery that there is an early mitochondrial involvement
in the apoptotic cascade [103,106] (Fig. 1). The re-
lease of cytochrome c from the intermembrane space
has been reported as an early event activating the
product of a gene (corresponding to ced-3 in the
nomenclature of the activation sequence of the nem-
atode Caenorhabditis elegans), which is caspase-3 (a
cysteine-aspartate protease) [108^111]; this activation
requires the product of the ced-4 gene [112] and is
inhibited by ced-9 or Bcl-2 and similar proteins
[110,111,113^115]. The proteins of the Bcl-2 family
are localized in the outer mitochondrial membrane
[116], where pro-apoptotic proteins such as Bax and
Bad, structurally related to the former, are also
present [117]. Since opening of the permeability tran-
sition pore, with fall of the mitochondrial membrane
potential, also represents a fundamental step in
apoptosis [103,106,118], and Bcl-2 may also prevent
pore opening [119], the relation between cytochrome
c release and pore opening is still controversial :
whether the latter phenomenon, with consequent
swelling and rupture of the outer membrane, is the
cause of cytochrome c release, as it happens in iso-
lated mitochondria [120,121], whether cytochrome c
loss and consequent alteration of the respiratory
chain induce pore opening, or whether they are two
independent phenomena. The fact that Bcl-2 and re-
lated proteins can polymerize [122] to form large
channels in the membrane [123,124] has suggested
Fig. 3. A decreased electron transfer to oxygen via the CoQ pool may be masked, when assaying complex I activity, by concomitant
reduction of the exogenous quinone acceptor by electrons £owing through both the physiological site and a non-physiological site (cf.
[40]). A decreased electron £ow to oxygen might depend on a decreased Vmax of NADH-CoQ10 reductase activity of complex I, but
also on its increased Km for CoQ10 in the pool. In fact such a higher Km may be responsible for decreased electron £ow to oxygen,
since the physiological CoQ10 concentration in the inner mitochondrial membrane is not saturating for NADH oxidation [176].
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that such channels in the outer membrane may allow
the release of cytochrome c in the cytosol [117,123].
Oxidative stress may not just be one out of several
signals committing the cell to apoptosis, but repre-
sent an early intrinsic component of any apoptotic
cascade, since an oxidative stress component was
shown in apoptosis induced, among others, by p-53
expression [125], by dexamethasone [126], and by
ceramide [127]; in the latter, the oxidative step was
identi¢ed in complex I of the respiratory chain [127].
Although oxidative stress is one of the causes of
pore opening [79], the commitment to apoptosis
seems to be an earlier event, at least in some forms
of apoptosis [128]: induction of pro-apoptotic pro-
teins and cytochrome c release seem to occur before
any decrease of the mitochondrial transmembrane
potential can be shown [110,111].
5. Mitochondrial cytopathies as a model for ageing
The discovery that mtDNA mutations are at the
basis of a number of human pathologies [129] has
opened a new and extremely active chapter of mito-
chondrial research [130^132]. Not all mitochondrial
cytopathies are due to mtDNA mutations, but many
are due to mutations in nuclear genes encoding for
mitochondrial proteins [133,134]. The diseases due to
mtDNA mutations, contrary to those of nuclear
genes, are genetically well characterized. There are
diseases due to point mutations of a structural gene
and others due to mutations in tRNA genes; in ad-
dition sporadic or familiar forms characterized by
extensive deletions of mtDNA are also described
[129^134].
Mitochondrial genetics is peculiar for many re-
spects when compared with mendelian genetics
[132,134]: besides the maternal type of transmission,
the presence of multiple mtDNA copies in the same
cell (polyplasmy) and the possibility for a mutation
to experience di¡erent degrees of heteroplasmy are at
the basis of the threshold e¡ect, by which a pheno-
typic lesion becomes evident only when over 80% of
the mtDNA in a cell is mutated, and of mitotic seg-
regation, by which the proportion of mutant mito-
chondrial genomes may shift in daughter cells during
cell division; surprisingly, the process appears to be
non-random, so that di¡erent genotypes segregate to
di¡erent extents in di¡erent tissues during embryo-
genesis [135,136], a ¢nding that can have strong rele-
vance to ageing (Section 6).
Mitochondrial structural genes encode for 13 pol-
ypeptide chains belonging to those complexes of the
inner mitochondrial membrane which are involved in
the transmembrane movement of protons. Thus, the
phenotypic consequence of a mtDNA mutation must
be a defect in the oxidative phosphorylation machi-
nery of mitochondria [129].
A lesion in a structural gene, such as due to a point
mutation, would interfere with the function of the
polypeptide encoded by that gene, leading to enzyme
activity decrease. Indeed this is often found in such
kinds of cytopathies, such as a form of Leber’s
hereditary optic neuropathy (LHON), characterized
by a mutation in the genes for the ND1 subunit of
complex I at position 3460 of mtDNA [137], but not
in the form harboring the 11 778 ND4 mutation,
where complex I activity is unchanged [138]; in spite
of normal complex I activity, the £ux over the entire
respiratory chain is signi¢cantly decreased [138].
The ¢nding that in the 11 778 ND4 mutation there
is a decreased sensitivity to rotenone [139] and a
decreased a⁄nity for a quinone homolog used as
the acceptor [139,140] agrees with the notion that
the seven ND subunits of complex I are hydrophobic
polypeptides belonging to the sector of the enzyme
where a large series of inhibitors and the electron
acceptor CoQ are bound [141]. Since the quinone-
binding sites are also involved in the proton trans-
location activity of the complex [141,142], it is pre-
dictable that a defective energy conservation may be
present in this form of the disease.
The decreased respiratory rate in spite of normal
complex I activity in subjects harboring the 11 778
ND4 mutation is puzzling; possible explanations
are either in a decreased a⁄nity of complex I for
endogenous ubiquinone (CoQ10), as indeed found
for an exogenous short CoQ homolog, CoQ2
[139,140], or in overestimation of the physiological
complex I activity due to electron withdrawal, by
the acceptor used, from a non-physiological site in
the enzyme [40,43], made available by an incorrect
assembly caused by the mutation [139].
Another cytopathy characterized by a mtDNA
point mutation, the NARP or maternally inherited
Leigh syndrome, associated with an 8993 mutation in
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the ATPase-6 gene [143], is characterized by de-
creased ATP synthesis [144], although the biochem-
ical defect has not yet been identi¢ed; in the light of
the above considerations, it would be speculated that
the primary defect involves proton translocation
through the F0 proton channel, as found by site-di-
rected mutagenesis to the homologous region of sub-
unit a of Escherichia coli [145].
On the other hand, a lesion in a gene encoding for
a mitochondrial tRNA, as in the MELAS and
MERRF syndromes [131], would interfere with mi-
tochondrial protein synthesis of all the subunits en-
coded by mtDNA.
Some forms of mitochondrial disease are caused
by mtDNA deletions [131]; being extended to large
portions of the mitochondrial genome, as the 4977
bp common deletion found in patients a¡ected by the
Kearns-Sayre syndrome [146] together with many
other deletions, and removing many genes including
essential tRNA genes [147], they strongly interfere
with mitochondrial function.
It was found that some mtDNA alterations, par-
ticularly deletions, are also present in normal indi-
viduals, though to very small extents, and accumu-
late with age [148]. In particular, the common
deletion of the Kearns-Sayre syndrome has often
been found by PCR to accumulate in postmitotic
cells in old individuals.
6. Mitochondria and ageing
The concept that mitochondria are primarily in-
volved in ageing derives from the theory of Harman
[149], linking senescence to the injurious e¡ect of free
radicals arising from the one-electron reduction of
oxygen during metabolism. In accordance with the
free radical theory of ageing is the inverse relation
existing between auto-oxidation rate in di¡erent ani-
mal species and life expectancy of the same species
[150,151]; the auto-oxidation rate on its hand is di-
rectly proportional to metabolic rate, so that the du-
ration of life seems to be inversely related to the rate
of oxygen consumption [152]. The increased longev-
ity obtained by caloric restriction in rodents
[153,154], which is accompanied by decreased state
4 respiration and decreased superoxide production
[154], and the relation of lifespan in Drosophila
with the simultaneous expression of the antioxidant
enzymes superoxide dismutase and catalase [155] are
corollaries of this proposal.
6.1. Mitochondrial theories of ageing
As pointed out in Sections 2 and 3, mitochondria
are the major sources of oxygen radicals through the
respiratory chain and are also deeply a¡ected by
ROS, resulting in serious risks to their function. In-
deed, a decreased mitochondrial performance has
been generally observed in senescence (cf. [156])
and, in principle, this decline could be due to alter-
ation of each one of the macromolecular components
above. The mitochondrial theory of ageing [157,158]
has attempted to de¢ne in precise molecular terms
the energetic changes accompanying senescence,
and can be represented as a re¢nement of the free
radical theory.
Brie£y, it was proposed that accumulation of so-
matic mutations of mtDNA, induced by continued
exposure to free radical attack, leads to errors in the
mtDNA-encoded polypeptide chains; these errors
are stochastic and randomly transmitted during mi-
tochondrial division and cell division. The conse-
quence of these alterations, which a¡ect exclusively
the four mitochondrial enzymatic complexes in-
volved in energy conservation, would be defective
electron transfer and oxidative phosphorylation. In
addition, respiratory chain defects may become asso-
ciated with increased production of ROS, thus estab-
lishing a vicious circle of mtDNA mutations and
oxidative stress [159]; the redox mechanism of ageing
[159,160] uni¢es both the ideas of the mitochondrial
theory [157,158] and of the free radical theory of
ageing [149] (Fig. 2). It is also established that oxi-
dative stress is a powerful cause of apoptotic death
(Section 4); therefore oxidative stress, ageing and
apoptosis are strictly linked events. It is conceivable
that an acute stress would trigger a mechanism in-
ducing cell death directly, whereas a milder stress
may slowly lead to impaired cell function as in age-
ing.
The mtDNA mutations are expected to accumu-
late and to lead to damage mainly in postmitotic cells
[161], where oxidative metabolism is very elevated as
in neurons or is subjected to high bursts as in skeletal
muscle; moreover, in postmitotic cells, the lesions
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could be conserved at di¡erence with mitotic cells
where division leads to selection with ‘washing
away’ of the defective cells [162].
6.2. Mitochondrial bioenergetics in ageing
The subject of age-dependent changes in mito-
chondrial bioenergetics abounds in con£icting data,
e.g. reporting declines of respiratory enzymes or
ATPase activity or unable to ¢nd signi¢cant di¡er-
ences (cf. [157,163]). There may be several reasons
for such con£icting data.
First, mitochondria when isolated are obtained
from tissues containing both di¡erentiated non-divid-
ing cells and relatively non-ageing dividing cells ; thus
small changes only in one population may become
undetectable [161]. Furthermore, energy-defective
cells may undergo elimination by apoptosis [164];
the continuous cell elimination when mitochondria
become de¢cient would prevent observing important
energetic changes in the remaining population.
If the energetic impairment derives from a stochas-
tic damage to the mitochondrial genes, then it is
important to select the mitochondrial activity which
is most likely to be a¡ected. Since seven out of the 13
structural genes in mtDNA encode for polypeptides
in complex I (NADH CoQ reductase), then it is com-
plex I that is most likely to undergo functional alter-
ations [165]. Unfortunately the assay of complex I
activity su¡ers from serious problems due to the
choice of the best quinone to be used as electron
acceptor [166]; in our laboratory it was found useful,
when possible, to assay this activity indirectly [167]
by exploiting the pool equation [168]
Vobs  VoUV r=Vo  V r
whereby the rate of CoQ reduction (Vr) is related to
total rate of NADH oxidation by oxygen (Vobs) and
to rate of ubiquinol oxidation (Vo). Using this meth-
od, signi¢cant decreases of NADH CoQ reductase
activity, undetected by the direct assay, were revealed
in liver and heart mitochondria from 24-month-old
rats [167], presumably by providing more accurate
values of NADH CoQ reductase activity.
Another approach employed in our laboratory for
recognition of possible early changes not only in
postmitotic cells but also in short-living cells, such
as blood platelets, has been looking for speci¢c
changes linked to subunits encoded for by mtDNA;
in analogy with previous ¢ndings in LHON [139], it
was found that rotenone sensitivity of NADH CoQ
reductase was signi¢cantly decreased in platelets
from old individuals [169]. The same change was ex-
hibited by non-synaptic mitochondria from rat brain
cortex [170].
A decrease of an individual enzyme activity in a
metabolic pathway is meaningful only if it is able to
a¡ect the rate of the whole pathway, and this will
depend on the degree of £ux control exerted by the
individual step [171]: in the respiratory chain, com-
plex I is present in lowest amounts [62], then it is
presumably the rate-limiting step of aerobic NADH
oxidation [172]; however, this is not true for the
oxidation of NAD-linked substrates in phosphorylat-
ing mitochondria [173,174]. In mitochondrial dis-
eases, the £ux control coe⁄cient at site I in permea-
bilized cells was found to dramatically increase [175];
unfortunately this point has not been addressed in
studies on ageing.
The opposite phenomenon, i.e. the mentioned de-
creased respiratory rate accompanied by unchanged
complex I activity, detected in livers and hearts of
aged rats [167], was ascribed to inadequacy of com-
monly used acceptors; in analogy with a similar be-
havior in the LHON 11 778 ND4 mutation, an in-
correct assembly of the complex, witnessed by a
decreased rotenone sensitivity of its activity
[169,170], and leading to artifactual pathways of elec-
tron transfer to short chain quinones [40,43], might
explain the observation in molecular terms (Fig. 3).
Alternatively, a decreased a⁄nity for endogenous
CoQ might explain this apparent paradox, since
CoQ concentration is not saturating for NADH ox-
idation [176]. The latter possibility has not been ex-
plored in ageing; in view of the analogous ¢nding of
decreased rotenone sensitivity in ageing as well as in
LHON mutations, where the Km for a CoQ homolog
is also increased [139], this point is obviously worth
investigation.
Additional evidence on a respiratory impairment
in senescence concerns histochemical detection of a
loss of cytochrome c oxidase activity (but not of
succinate dehydrogenase) in muscle mitochondria
from old individuals [177]. The mosaic distribution
of the cytochrome oxidase lesions is well in agree-
ment with the stochastic distribution of mitochon-
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drial damage predicted by the mitochondrial theory
[164].
6.3. Mutations and deletions of mtDNA
Point mutations in mtDNA are present in normal
individuals and were claimed to increase with age
[178,179]; a careful study by quantitative PCR of
the frequency in skeletal muscle of two point muta-
tions observed in mitochondrial diseases has revealed
that the mutations are present at very low percent-
age, but there is no correlation with age, at least up
to 70 years [180].
The matter is di¡erent with mtDNA deletions. The
so-called common deletion, observed to high extents
in some mitochondrial disorders, was also found to
increase exponentially with ageing, particularly in
muscle and brain tissues [148]. Careful quantitation
by a competitive PCR method revealed that this sin-
gle deleted species was present in aged muscle at the
level of only 0.1% of total mtDNA. Thus, it may be
questioned whether detection of deleted mtDNA in
the elderly only represents an epiphenomenon of the
primary pathogenetic event, since very high levels of
damage are necessary to elicit activity changes, in
accordance with the threshold e¡ect. It has to be
borne in mind, however, that other deletions have
been found to increase in ageing [148]. Thus, even
though any single species of deleted mtDNA is
present at low levels, the total amount of deleted
mtDNA may reach levels that could be signi¢cant
in terms of oxidative phosphorylation decline. Oza-
wa, by systematic use of PCR primers over the entire
mDNA, found a progressive age-related fragmenta-
tion of mtDNA into various size deleted molecules
up to 358 types, with a strong correlation with 8-
hydroxy-D-guanosine accumulation [92,96,181];
mtDNA fragmentation also occurred in premature
ageing [182]. Deleted forms of mtDNA lacking rep-
lication origins accumulated up to 280 types out of
358. Concomitantly, wild type mtDNA decreased
down to 11% of total. Similar fragmentation of
mtDNA [183,184] and extensive oxygen damage to
tissues [185] was demonstrated in patients with mito-
chondrial cardiomyopathy, harboring hazardous
germ-line point mutations; therefore the mitochon-
drial diseases seemed to be derived from premature
ageing of the tissues.
A proof of the existence of a vicious circle of ox-
idation and mtDNA damage [159] requires demon-
stration that ROS production and their e¡ects in-
crease in ageing. It was indeed shown that
hydrogen peroxide generation increases with age,
e.g. in di¡erent species of £ies [151] and in isolated
rat hepatocytes ([186,187]; Cavazzoni and Lenaz, un-
published observation), although peroxide overpro-
duction in ageing was not found by others (cf.
[188]). Increased production of ROS is also inferred
from the increase of oxidized cellular components
with age [3,4,72,160], although this accumulation
may also result from impaired disposal of the dam-
aged species (cf. [189]).
According to the above view, the accumulation of
mtDNA lesions with ageing derives from an unbal-
ance in the rate of generation of ROS and their re-
moval [159,160]; an alternative or additional explan-
ation is that there is a relatively constant rate of
generation of the mutations, leading to synthesis of
aberrant proteins, but that in young animals cells
exhibiting those mutations are eliminated by immu-
nosurveillance by cytotoxic T-lymphocytes; since the
protective immune response declines with age, lead-
ing to an altered repertoire of antigens recognized
[190], one would expect an accumulation of cells con-
taining altered mtDNA (H. Baum, personal commu-
nication). In the light of the above hypothesis, the
decline in immunosurveillance with ageing may also
well re£ect somatic mutations of lymphocyte
mtDNA (cf. [191]).
The signi¢cance of mtDNA deletions in ageing is
emphasized by the species speci¢city of their time of
arousal: mtDNA deletions accumulate in organisms
with life spans signi¢cantly shorter than those of hu-
mans, at ages when there is no detectable deletion in
humans [192]. To this purpose, when using rodents
as experimental models for human ageing, the appro-
priate tissues should be considered, since not all tis-
sues of rats accumulate mtDNA deletions in the
same manner as those of humans [193].
6.4. Mitochondria-nucleus interplay in ageing
The available evidence suggests that mtDNA dele-
tions accumulate to su⁄cient extents to be able to
represent the cause for the respiratory chain and ox-
idative phosphorylation defects observed in ageing
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[148]; the proof that this is indeed the case, however,
is still lacking. The reason why deletions but, per-
haps, not point mutations accumulate in ageing is
not clear, although it may depend on the DNA re-
pair capabilities of mitochondria [194]. Oxidative
stress can lead to mtDNA deletions [92,94,95],
although these can also arise from altered nuclear-
cytoplasmic interactions. In fact an autosomal dom-
inant form of PEO (paralysis of extraocular
muscles), characterized by multiple mtDNA dele-
tions, indicates that it is a nuclear gene product
that a¡ects the proclivity of mtDNA to su¡er dele-
tions [195]. Whether this is also the case for mtDNA
deletions occurring in ageing is not known. The ob-
servation that oxidative phosphorylation defects in
cultured cells from aged donors could be reversed
by constructing cybrids where the nucleus from the
old donor was substituted by a nucleus from an im-
mortalized cell suggested that a nuclear mutation
might be responsible for the mitochondrial de¢cit
[196]; a subsequent extended study [197], however,
demonstrated the formation of several respiratory-
de¢cient clones by fusing mitochondria from ¢bro-
blasts of aged donors with a mtDNA-less b0 cell line,
as well as a signi¢cant decrease of respiration rate
and of mtDNA content with the age of the donors.
The results of the previous study [196] were ascribed
to selection of respiratory competent clones during
fusion.
Some additional observations on mitochondrial
changes in ageing appear di⁄cult to be directly ex-
plained by the mitochondrial theory. The decreased
mtDNA transcription in heart and brain of aged rats
[198] and the decreased rate of mitochondrial protein
synthesis in human muscle [199] have suggested the
existence of some more subtle defect in the interplay
between nucleus and mitochondria. However, the
¢ndings that deleted mtDNA often lacks replication
origins [159] and that the deletions usually encom-
pass several tRNA genes may o¡er explanations in
line with the mitochondrial theory. The suggestion
that mitochondria in aged cells may increase in size
[161,187,200,201] would also be in line with this ex-
planation, as a sign of impaired mitochondrial divi-
sion [160,161].
The dramatic changes in lipid composition ob-
served in ageing, particularly the fall in cardiolipin
content [202] and its relation with cytochrome oxi-
dase activity [68,69], suggest that other factors, re-
lated to oxidative stress but not involving mtDNA,
may be important pathogenetic events in the ageing
process. The ¢nding that a decreased rotenone sensi-
tivity of NADH CoQ reductase is observed in plate-
lets from old individuals [169], but that the ‘common
deletion’ is not observed in mtDNA from the same
cells [203], in contrast with a previous study [204],
throws some uncertainty over the mtDNA damage
as the only source of bioenergetic defect. Clearly, a
mitochondrial involvement in ageing is present,
though a unique role of mtDNA has yet to be estab-
lished.
7. Mitochondria and age-related diseases
The possibility that some of the most common and
devastating degenerative diseases of old age have a
mitochondrial involvement has been seriously con-
sidered in recent years [205^207]. Evidence pertaining
to this point will be only brie£y summarized here. In
particular an impairment to energy metabolism due
to progressive failure of the mitochondria has been
invoked in the pathogenesis of Alzheimer’s disease,
Huntington’s disease, Parkinson’s disease, and cere-
bellar degenerations. A common denominator of
these diseases, a¡ecting di¡erent speci¢c brain areas
with cellular atrophy, may be a reduced oxidative
metabolism and ATP synthesis, leading to membrane
depolarization with consequent activation of the glu-
tamate NMDA channels and excitotoxic cell death
[206], similar to the acute death produced by gluta-
mate release in ischemia-reperfusion injury [208]. The
observation that mitochondrial dysfunction in nerv-
ous tissue induces excitotoxic responses agrees with
this hypothesis [209].
In Alzheimer’s disease, the a¡ected brain areas ex-
hibit an increased production of 8-hydroxy-2-D-gua-
nosine from mtDNA with respect to age-paired con-
trols [96^98], an indication of enhanced oxidative
stress in the diseased brain; the mtDNA deletions,
however, were found to be decreased with respect to
age-matched controls, shedding doubt on the signi¢-
cance of the deletions, at least in concern with the
disease [210].
A severe compromission of complex I has been
found in the substantia nigra of subjects with Par-
kinson’s disease [211], and also, though less evident,
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in muscle and in platelets and lymphocytes of dis-
eased individuals [207,212]. The lowered levels of re-
duced glutathione in the substantia nigra of asymp-
tomatic Parkinson’s carriers with Lewy bodies [213]
militates for an early involvement of oxidative stress
in the pathogenesis of the disease [83]. The involve-
ment of mtDNA deletions or mutations is not prov-
en with certainty [214,215]. It was suggested that
certain point mutations occurring as polymorphisms
in mtDNA may serve as risk factors for neurodegen-
erative diseases [216]; the concomitant lesions due to
ageing and to environmental stress would gradually
impair mitochondrial function leading to excitotoxic
cell death and progressive atrophy of the interested
area. The complex I defect present in platelets from
Parkinson patients was transferred to fusion cybrids,
indicating a possible mtDNA defect [217]. The fact
that some brain areas seem to be more susceptible to
mtDNA damage in comparison with others may be
related to the speci¢c localization of neurodegenera-
tive diseases [83]. The picture is emerging that most
degenerative diseases originate from a concomitance
of risk factors enhancing the danger of oxidative
stress and energy failure in speci¢c tissues.
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